This partnership aims to produce the medical radioisotope Lutetium-177 (Lu-177), which is vital for advanced cancer treatments. 

The agreement formalises the terms of cooperation for developing the Lu-177 production project at the Cernavodă nuclear power plant, including the installation of Framatome patented technology at Unit 2. 

The project is in Phase 1, with equipment installation scheduled to take place during a planned shutdown in May 2027.

Framatome will bear the direct costs of the investment and operation of the system, recovering these from the total value of future sales. 

In return, Framatome will pay SNN an irradiation fee, calculated as a percentage of total sales. Nuclearelectrica will cover the indirect operational costs. 

As part of the agreement, SNN is guaranteed priority access to 4,000 Lu-177 treatment doses per year for domestic drug manufacturers, starting in the second year of commercial operation. 

Framatome will also donate doses equivalent to at least 20 treatments annually for non-profit purposes.